Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in.
Justices look for line to draw in drug preemption case
WASHINGTON – Deciding where the preemptive effect of federal rules governing drug manufacturing ends and states’ ability to impose liability on drug makers begins has never been an easy task — not even for the justices of the U.S. Supreme Court. On Tuesday, the justices wrangled once again over the preemptive reach of the federal Food, Drug and Cosmetic Act in an effort to decide whether the law prevents design defect claims against generic drug manufacturers.